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Summary.-The effect of 5-fluorouracil (5-FU) on the growth and cellular pro-
liferation of hepatoma 3924A was studied using the following parameters as indices
of tumour response: (1) volume measurements, (2) cell kinetic analysis including
estimates of both growth and cell loss fractions, (3) changes in tumour histology
and (4) tumour DNA content and DNA synthesis. Of a series of single intraperi-
toneally injected doses (25-300 mg/kg body weight), 150 mg/kg interrupted tumour
growth most effectively with minimal toxicity within 168 h, and after 10 days treated
tumour volumes were only42% of untreated tumour size. Doses of25 mg/kg failed
to change the rate of growth while 300 mg/kg exceeded the LD50.
Alterations of both tumour cell proliferation and histology developed well in
advance of changes observed in growth. A dose of 150 mg/kg body weight blocked
the transition of cells from G1 through S for a 24 h interval when cell kinetics were
measured by 3H-TdR autoradiography. However, 3H-UdR incorporation into
DNA following 5-FU suggested that cellular recovery from the drug was delayed
for an additional 24 h. Concurrently, significant losses of tumour tissue and tumoiir
DNA occurred during the first 48 h with an expected increase in both necrotic add
connective tissue. During the subsequent 120 h both tumour and necrotic tissue
had returned to non-treated levels, while kinetic analysis revealed (a) a slight reduc-
tion in the cell cycle time and growth fraction and (b) an increased cell loss factor.
The observations from this tumour model system suggest that before using tumour
volume or weight as an index of therapeutic response, the relationship between the
kinetics of tumour cellularity and tumour volume must be defined.
5-FLUOROURACIL (5-FU) has been
evaluated as a chemotherapeutic agent
(Carter, 1970; Greenwald, 1967; Harrap,
1973) and many aspects of both the
cellular and molecular pharmacology have
been studied in vitro (Adams, Breed and
Valenti, 1967; Kent and Heidelberger,
1972; Madoc-Jones and Bruce, 1967,
1968; Rich et al., 1958) as well as in
vivo (Chadwick and Rogers, 1972; Skipper,
1971; Vietti, Eggerding and Valeriote,
1971; Wolberg, 1972). However, a com-
prehensive study of the effects of 5-FU
on the growth and cellular kinetics of
both normal host and target tissue has
not been reported.
Like many of the anti-neoplastic
agents in clinical use, 5-FU exerts its
main effects on rapidly dividing cells.
The conversion of 5-FU to 5-fluoro-
deoxyuridylic acid blocks the synthesis
of dTMP from dUMP and thus inhibits
DNA svnthesis (Birnie, Kroeger and
Heidelberger, 1963; Bosch, Harbers and
Heidelberger, 1958). 5-FU can therefore
effectively block normal cell renewing
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populations of the host as well as the
target tumour tissue. For chemothera-
peutic scheduling, comparative knowledge
of the effects of 5-FU on both normal
cell renewal populations and target tissue
is of importance. In this report, we
shall consider both immediate as well as
prolonged 5-FU induced perturbations
of solid tumour growth and related
cellular proliferation.
MATERIALS AND METHODS
Tumoour growrth. Female ACI rats were
inoculated subcutaneously in the back with
3924A hepatoma cells by Dr H. Morris in
Washington and shipped to this laboratory.
The rats were maintained under a 12 h
lighting schedule, the dark period beginniing
at 8.00 p.m., and commercial laboratory
rat chow (Charles River Laboratories, Wilm-
ington, MEass.) was supplied ad libitum.
Tumour volumes (mm3) were calculated
(2L x W x H)frommeasurementsoflength,
width and height made 3 times weekly,
unless otherwise specified. Variability of
growth rates of individual tumours deter-
mined by this method decreases considerably
after individual tumours have reached a
minimum of 200 mm3 (Looney et al., 1973).
For this reason, experiments were scheduled
when animals could be grouped uniformly
with a mean tumour volume of200 4- 50 mm3
or larger.
5-Fluorouracil (Roche Laboratories, Hoff-
man-LaRoche, Inc., Nutley, N.J.) prepared
in sterile saline was administered by intra-
peritoneal injection (i.p.) between 8.00 and
8.30 a.m.; control animals were injected with
saline.
3H-6-Deoxyaridine incorporation and DNA
content of tumours.-To avoid the possible
role of thymidine in overcoming or obscuring
any effect of 5-FU on DNA synthesis, the
incorporation of 3H-deoxyuridine (3H-6-
UdR) into DNA was used to evaluate changes
in DNA synthesis following 5-FU injection.
Three 5-FU treated and 3 non-treated
animals were injected (i.p.) at each time
point with 50 FuCi of 3H-6-UdR (sp.
act. 17 Ci/mmol, Schwarz-Mann, Orange-
burg, N.Y.). Sixty min later, the animals
were killed and the tumours were excised,
rinsed in saline, weighed and frozen.
DNA was extracted by an adaptation
(Hopkins, Flora and Schmidt, 1972) of
the procedures of Schmidt and Thannhauser
(1945) and of Schneider (1945). DNA was
measured in the trichloroacetic acid extracts
by the method of Burton (1956), but H2SO4
was omitted, diphenylamine was increased
to 2 g/100 ml and HC104 was present at
a final concentration of 0 4 mol/l. Highly
polymerized DNA (Sigma Chemical Co., St
Louis, Mo.) was the standard. Radio-
activity in the DNA extracts was measured
in
" cocktails " described by Patterson and
Green (1965) on a Beckman LS-150 liquid
scintillation counter.
Cell cycle determinations.-One week fol-
lowing administration of 5-FU, after all
tumours had re-established their growth
rate, a single i.p. injection of 50 ,uCi tritiated
thymidine (3H-TdR, sp. act. 3 Ci/mmol,
Schwarz-Mann, Orangeburg, N.Y.) was given
to each animal. At designated intervals
during the subsequernt 100 h, tumours were
excised, bisected, fixed in 10% buffered
formalin and embedded in Paraplast. The
tissue was sectioned at 4 ,um and the sections
stained with haematoxylin and eosin. Auto-
radiographs were prepared with Kodak
AR-10 and the slides exposed at 4°C for
14 days for each tumour excised during the
first 24 h interval following 3H-TdR injection,
and for an additional 14 days for each
additional 24 h interval following 3H-TdR
injection thereafter. Slides were developed
with Kodak D-19 and fixed with 20%
sodium thiosulphate. For each tumour, the
percentage of labelled cells was determined
from 2250 cells and the percentage of
labelled mitotic figures from 150 mitoses.
Estimates of the growth fraction in
tumours were made by determining the
ratio of the experimentally determined 1 h
labelling index (LIeXp) to the theoretical
1 h labelling index (Lltheor).
Lltheor = iT./T,
where A is the constant of proportionality (Steel,
1968) and T, and Tc are the duration of the S phase
and cell cycle respectively.
G.F. = LIexpIA T,
The potential doubling time (T) as
defined by Steel (1968) was determined from
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the L.I. and was used to estimate cell loss
(s) by the following:
T = Ts/LIexp
= 1-T/Td
where Td is the actual doubling time determined
experimentally.
3H-Thymidine labelling index and tumour
pathology.-At intervals following treatment
with 5-FU, or saline for non-treated animals,
4 animals per group were given single
i.p. injections of 50 ,uCi 3H-TdR (sp. act.
3 Ci/mmol). After a 60 min interval, the
animals were killed and tumours removed.
Groups of animals were killed at 1, 3, 5, 12,
16, 24, 48, 72, and 168 h following 5.FU
treatment and autoradiographs were pre-
pared as described above. To determine
the relative proportion of tissue contents,
tumours were excised, fixed, embedded and
sectioned at 5 ,um. The sections were
stained with Masson-Trichrome. This stain-
ing procedure facilitates recognition of green
stained connective tissue elements and gives
good contrast between viable and necrotic or
degenerating tumour tissue. Sixteen to 20
sections (10 random fields per section) of
each tumour were analyzed by the nmethod
of Chalkley (1943) and the data expressed
as the relative percentage of total tissue
scored.
RESULTS
Tumour growth
The growth rate of hepatoma 3924A
decreases with increasing tumour volume
(Fig. 1). For tumour volumes of less
than 1000 mm3 the volume doubling
time (Td) was about 2-5 days. After
the mean tumour volume exceeded 1000
mm3 (Day 15), Td increased to about
4 0 days. This differs from a previous
report (Looney et al., 1973) where the
growth data for a number of hepatomata
including 3924A were approximated by
a single exponential function. This
method gave a Td of 4-35 days.
In preliminary experiments a series
ofsingle doses of 5-FU were administered,
ranging from 25 to 300 mg/kg body
weight: 25 mg/kg had little effect on
tumour growth whereas a dose of 300
mg/kg resulted in severe toxicity and
exceeded the LD50 (30 days). A dose of
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FIG. 1.-The effect of 5-FU on the growth of
hepatoma 3924A. (0 O), mean tumour
volume for 18 untreated, animals;
(0 0*), mean tumour volume for 18
5-FU treated animals.
150 mg/kg was optimal for reducing
tumour growth while maintaining toxicity
at a minimum and this dose was used
in the present work. The mean tumour
volume was 230 ± 40 mm3 when 5-FU
at 150 mg/kg was administered. At
48 h after treatment the tumour volumes
were 78% of those of non-treated animals
and at 10 days were only 42% of those
of non-treated animals (Fig. 1). The
volume doubling time of treated tumours
returned to a non-treated tunlour value
(Td = 40) 7 days after treatment.
Tumour composition and cellularity
Drug induced perturbations in the
size of the S phase compartment of the
cell cycle were studied by comparing the
1 h 3H-TdR labelling indices (L.I.) ob-
tained at varying intervals of time
following 5-FU treatment. The L.I. for
non-treated animals and for animals
treated with 150 mg/kg 5-FU are given
150mg/kg body weight 5-fluorouracil
I
10 15 20 25 30 355-FLUOROURACIL AND TUMOUR GROWTH PARAMETERS
40
a.
C9"
30
a
20
10 z
V
24 48 72 96 120 144 168
TIME (h)
FIG. 2. The' effect of 5-FU onithe S phase
population of hepatoma 3924A. (0°- 0),
% labelled interphase cells in non-treated
tumours; (0 *) % labelled interphase
cells in tumours treated with 150 mg/kg
body weight 5-FU. Each point represents
the mean for 4 tumours.
in Fig. 2. Following treatment, the
increase in L.I. between 0 and 24 h
represents an accumulation of cells in
the S phase or at the G1/S boundary.
The L.I. falls rapidly between 24 and
48 h after treatment, approaching non-
treated values. For hepatoma 3924A the
L.I. is relatively constant over a tumour
volume range of 60 to 900 mm3 (Table I).
Within these volume limits the mean
L.I. was 16 ± 066% of the tumour
population.
The tissue composition of hepatoma
3924A was analysed over a range of
tumour volumes and there appeared to
be no correlation between tumour volume
and the relative tissue composition (Table
I). In fact, for tumours with volumes
ranging from 70 to 350 mm3, the tissue
composition remained relatively constant
at 510o tumour, 18% necrotic, 26%
connective aild 500 blood.
Tissue composition was analysed fol-
lowing treatment with 150 mg/kg 5-FU
(Fig. 3). 5-FU was effective in reducing
the relative number of viable tumour
cells within 48 h of treatment; tumour
tissue decreased to 50% of non-treated
tumour values. Concomitantly, increases
in both necrotic and connective tissue
were observed. After 48 h, the relative
tissue composition began to return to
non-treated values.
DRA content and 3H-deoxyuridine incor-
poration
A corresponding increase in DNA
content with tumour weight occurs over
the range of tumour sizes used in these
studies (Fig. 4). This relationship
amounts to a concentration of 7-0 mg
DNA/g tissue. In tumours of similar
size the amount of tumour tissue relative
TABLE I. Labelling Index and Relative Tissue Constituents ofSections
from Tumours of Differing Sizes
Relative tissue constituents
Necrotic Connective Blood
19-5
16-6
13-7
19-6
20-(6
15-5
21 -4
16- 1
15-7
11-9
30- 7
33-5
28- 7
31 - 6
29 1
19-1
24- 1
25 1
51-1+1-5 17-64-0- 9 26-0-4-2-3
Tumour
volume
(mm3)
58
73
75
100
152
164
181
209
222
225
283
301
332
342
420
630
695
900
Tumour
58-6
49-6
48-9
48-6
42- 7
52-8
52-8
51-7
54-0
Labelling
index
13-7
17-2
12-6
13-0
20-3
18 1
21-5
19-2
14-9
17-5
15-5
12-5
16-3
15-5
15-7
17-5
15-5
17-5
16-3+0-6
9-6
3 1
3-9
3-0
5-0
2-7
6-7
7-9
5-2
45
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FIG. 3. The effect of 5-FU on the relative tissue composition of hepatoma 3924A. (0 * *),
tumour tissue; (0 -O), necrotic tissue; ( A). connective tisstue. Each point represents
the mean foi 4 tumouirs.
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FcIG. 4. The relationship between tumour
weight and tumour DNA content. Open
and close(c circles represent the values from
2 different sets of (leterminations. DNA
concentration is 7 0 mg/g/tumour tissue.
to necrotic, connective and blood tissues
and the cell density as determined by
counting the number of cells per micro-
scopic field have been found to remain
constant (Kovacs and Evans, unpub-
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Fi(e. 5. The effect of 5-FU on the DNA
content of hepatoma 3924A. (0 O)
mg DNA/g of tissue of non-treatedi
tumours; (0 0), mg DNA/g of tissue
of tumours treated with 150 mg/kg body
weight 5-FU. Each point represents the
mean for 3 tumoturs.
lished). DNA concentration, therefore,
was used in conjunction with histological
observations to estimate tumour cellu-
larity.
Within 48 h after treatment with
150 mg/kg 5-FU, there was a gradual
decrease in DNA concentration of the
drug treated tutnours (Fig. 5). By 7-8
days after treatment, DNA concentration
reached a nadir and gradual restoration
to the DNA concentration observed for
non-treated tumours occurred over the
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FIG. 6. The effect of 5-FU on the incorpora-
tion of 3H-deoxyuridine into DNA in hepa-
toma 3924A. (0 O), d/min/mg DNA
in non-treated tumours; (0 -0), d/
min/mg DNA in tumours treated with 150
mg/kg body weight 5-FU. Each point
represents the mean for 3 tumours.
subsequent 2 week period. This reduc-
tion of DNA/g tumour to 700o of that
for non-treated tumours reflects cell death
and eventual removal of dead cells
beyond the cell loss normally occurring
in growing tumours. However, giant
cell formation and continued accumula-
tion of connective tissue may also have
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contributed to the changes in DNA
concentration. Since protein/g tumour
was not affected by treatment with
5-FU, however, changes in water content
cain be ruled out as responsible for the
decrease in DNA concentration.
5-FU rapidly depressed the incor-
poration of 3H-deoxyuridine into tumour
DNA (Fig. 6). Minimal incorporation
occurred up to 36 h following 5-FU
injection (4% of non-treated value).
After 48 h, DNA synthesis recovered with
enhanced incorporation relative to non-
treated tumours on Days 8-14.
Cell proliferation
Per cent labelled mitoses (PLM) curves
were constructed for tumours treated
7 days previously with 150 mg/kg body
weight of 5-FU. At this time, growth
rate, labelling index and relative tissue
composition had either re-established con-
trol levels or at least stabilized (Fig.
1, 2, 3). The PLM data for 5-FU treated
and non-treated groups of tumours were
analysed by the computer method de-
scribed by Simon, Stroot and Weiss
(1972) and the curves obtained have been
TIME AFTER H3-TdR (h)
FIG. 7. PLM curves for non-treated and 5-FU treated hepatoma 3924A. (0 O), non-treated
tumours; (0 *), tumours treated with 150 mg/kg body weight 5-FU. ( ) computed
curve for control tumours; (----) computed curve for 5-FU treated tumours.
4
4748 C. J. KOVACS, H. A. HOPKINS, R. M. SIMON AND W. B. LOONEY
TABLE II.-Kinetic Analysis of 5-Fluo-
rouracil Treated Tumours
Non-treated
5-FU
(150 mg/kg)
Cell
cycle
time
27-9
24-2
Growth
fraction
66-5
60-8
Cell
loss
factor
0-61
0-56
Actual
tumour
doubling
time
(h)
96
96
reproduced in Fig. 7. For non-treated
tumours, PLM reached a maximum of
940/ while maximum PLM of tumours
receiving 150 mg/kg was 83%. PLM
data analyses show a 3-7 h decrease in
cycle time with both Tg1 and Ts decreasing
while Tg2 increased (Fig. 7). These
changes, however, are not of significant
magnitude to affect the growth rate of
these tumours. The growth fraction of
non-treated tumours was 66-5 (Table II).
For treated tumours, 150 mg/kg reduced
the growth fraction to 60-8. Cell loss for
tumours treated with 150 mg/kg 5-FU
was calculated to be 0-56 compared with
0-61 for the non-treated tumours (Table
II).
DISCUSSION
The growth of solid tumours, as we
know it, is a function of (a) the fraction
of proliferating cells, (b) the rate of
cell loss and (c) the amount and type
of cellular material present in the tumour
(see Lala, 1971, for review). The results
presented here are from studies designed
to relate quantitatively the effects of
5-FU at a cellular level with the observed
retardation of tumour growth. Methods
available for growth fraction (Mendel-
sohn, 1962; Steel, Adams and Barrett,
1966) and cell loss (Steel, 1968) deter-
minations by 3H-thymidine incorporation
do not account for wide fluctuations
resulting from residual synchrony from
the pulse label and from the transition
of growing to non-growing cells. Per-
turbations in cellular proliferation and
cell killing resulting from cycle-specific
drugs such as 5-FU would only magnify
the fluctuations in both these parameters.
For this reason cell kinetic parameters
were studied 7 days post-treatment, when
the growth of treated tumours had
stabilized.
Immediately following 5-FU injection,
cells were prevented from either initiating
or completing DNA replication and the
S phase and G1/S phase compartments
expanded for a 24 h interval (Fig. 2).
Simultaneously, the 3H-deoxyuridine in-
corporation into DNA was depressed
(Fig. 6) and remained depressed for 48 h
before returning to non-treated levels
and eventually overshooting at Day 8-14.
This additional 24 h depression in 3H-UdR
incorporation, not observed in the 3H-TdR
labelling index, suggests a retarded rate
of initiation of DNA replication and cell
cycle traverse following 5-FU treatment.
It may also reflect the presence of non-
viable or degenerating cells which contri-
bute to both the DNA content and the
interphase cell number but are unable
to incorporate 3H-UdR. The injection
of 3H-TdR may serve much the same
function as TdR as a rescue agent on
thymidine starved cells (Madoc-Jones and
Bruce, 1968; Rueckert and Mueller, 1960),
providing misleading data on cell viability
and proliferation status.
The reciprocating levels of necrotic
and viable tumour tissue reflect a killing
of cells with cell death reaching a maxi-
mum at 48 h following treatment. From
our data, it appears that the removal
of necrotic cells from 3924A is a slow
process requiring 7 days (168 h) to reach
pretreatment levels (Fig. 3). Over the
same period, the loss in DNA content
reflects the removal of cells from the
tissue. However, DNA content does not
return to pretreatment levels until Day 21
(Fig. 5). This discrepancy between kin-
etic histological and biochemical estimates
of cellular response to 5-FU may be
explained by a decrease in viable cell
density within the tumour tissue. Deth-
lefsen and Riley (1973) have suggested
that in drug treated tumours, the normal
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another (e.g., proliferating to degenerat-
ing) is shifted in favour of repopulation
until pretreatment conditions are restored.
If this shift occurs in 3924A, then the
decrease in necrotic tissue observed after
48 h could result from both a dilution
with new viable cells as well as the
normal removal of necrotic tissue. How-
ever, the loss of DNA from treated
tumours (Fig. 5) corresponds well with
the time course of necrotic tissue removal,
suggesting that removal of dead cells
from 3924A arises early after treatment
and continues until Day 7-8 post treat-
ment. Furthermore, the earliest that
repopulation could be initiated would
be after Day 4 when the 3H-UdR incor-
poration begins to increase. Denekamp
and Thomlinson (1971), Denekamp (1972)
postulate that during the period of
radiation induced mitotic delay, the cell
loss occurring normally in tumours is
unmasked and the tumour volume re-
sponse is a function of the cell loss factor
of the individual tumours. Unfortunate-
ly, application of Denekamp's postulate
could not be made for 5-FU treated
3924A hepatomata since mitotic delay
was not demonstrable. The mitotic fre-
quency following 5-FU, while decreasing
from 045 to 0 09 24 h post treatment,
returned to normal without a rapid rise
normally associated with mitotic delay
(Kovacs, unpublished observation). The
possibility exists, however, that even
during the period of mitotic depression
cell loss occurs normally, resulting in
the loss and removal of tumour cells
with few replacement cells.
From Table II the effects of 150 mg/kg
5-FU on several parameters of tumour
growth can be compared. At this dose,
a significant retardation oftumour growth
was observed within 48 h after treatment.
However, the average doubling times of
the non-treated and the treated tumours,
once they began to regrow, were both
found to approximate 96 h. Both the
cell cycle time, growth fraction and cell
loss factor were somewhat decreased.
Wilcoxandhis coworkers have observed
that following chemotherapy, the cells
killed by a drug became non-viable
promptly (Wilcox et al., 1965). Shortly
after treatment, the growth of viable
cells and the removal of non-viable cells
both in leukaemic mice (Wilcox, 1966)
and in several experimental solid tumours
(Wilcox et al., 1965) return to near
control levels. Therefore, the rate of
treated tumour growth is eventually
controlled by the number of viable cells
that are proliferating. Our observations
with tumours treated with 150 mg/kg
5-FU support WAilcox's findings. The
early loss of 5-FU killed cells and the
delay in reinitiating cell proliferation
post treatment are apparently responsible
for the response in tumour growth to a,
single injection of 5-FU at this dose.
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